• Little Green Pharma completes commissioning of cultivation facility expansion on time and on budget
• Expanded cultivation facility will allow the production of up to 110,000 bottles of medicinal cannabis oil per annum, approximately 10 times the current capacity
• First planting targeted for Q2CY2020, subject to Office of Drug Control permitting
• Expansion of LGP’s cultivation capacity will assist in fulfilling sales agreements for the German and UK markets
Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) is pleased to announce the completion of the commissioning of its expanded cultivation facility in Western Australia.
The facility expansion was commissioned on time and on budget using state-of-the-art equipment, enhancing the Company’s ability to produce GMP manufactured medicinal cannabis. The expanded cultivation facility will have the capacity to produce sufficient cannabis flower to manufacture more than 110,000 bottles of medicinal cannabis oil per annum, approximately ten times the current production capacity.
The expanded cultivation facility features nine new flowering rooms with a number of automated technologies to enhance cultivation effectiveness, such as rolling benches, computer-timed LED lighting, climate control, and irrigation control.
The facility will operate under its expanded Medicinal Cannabis Licence, which was granted by the Office of Drug Control (“ODC”) (as announced to the ASX on 12 March 2020) and is valid until 10 March 2021.
Subject to final regulatory approval and the granting of an expanded Medicinal Cannabis Permit by the ODC, including any potential delay to the permitting process due to the impact of COVID-19, LGP expects first planting at its expanded cultivation facility to take place in Q2CY2020.
Commenting on the completion of the facility expansion commissioning, LGP Managing Director Fleta Solomon said: “It is pleasing to see the hard work by our staff come to fruition through the completion of this expanded cultivation facility. The Company has signed sales agreements into some of the world’s largest medicinal cannabis markets, including Germany and the UK, and this expanded facility represents a major milestone in enhancing our ability to improve the lives of patients in Australian and international markets.”